BPC-157 + GHK-CU + TB-500 + KPV

This SKU combines BPC-157, GHK-CU, TB-500, and KPV into a single product. Together, these peptides are often referenced in discussions around tissue repair, cosmetic applications, and inflammation in experimental contexts.

The listing is structural, indicating which peptides are bundled together. It does not imply that the combination is supported by strong evidence or guidelines.

Conceptually, combinations like this attempt to layer several mechanistic themes:

• BPC-157 and TB-500: experimental work related to tissue repair and inflammatory modulation
• GHK-CU: cosmetic and wound-healing narratives linked to copper-binding peptides
• KPV: tripeptide fragment discussed in relation to anti-inflammatory and gut-related effects

How these themes interact in a single product, and whether combination use is advantageous or safe, is not well established in high-quality human data.

In regulated medicine, these peptides—individually or in a four-part combination—are generally not approved therapies for healing, cosmetic, or anti-inflammatory indications. They are more commonly found in research or gray-market channels.

This context makes it especially important to distinguish between hypothesis-generating ideas and established standards of care.

Potential risks include local injection-site reactions, nonspecific symptoms such as headache or fatigue, and unknown long-term effects of sustained exposure to multiple experimental agents.

Because the safety profile is uncertain, clinicians tend to emphasize caution, especially when robust, regulated alternatives exist.

This "Wolverine" style blend combines multiple active agents. Dosing is often limited by the GHK-Cu component, which can be painful or toxic at high doses.

This information summarizes commonly discussed research practices.

A four-peptide vial is a four-way labelling claim, and at least one of those claims has been tested independently — with poor results. Testing performed by the UC Davis Maddy Laboratory for the Racing Medication and Testing Consortium found that many products labelled TB-500 contained no thymosin beta-4 or derived peptide, and most contained no protein, peptide, or amino acid at all (RMTC drug bulletin).

The naming is also unstable. "TB-500" is normally a synthetic copy of residues 17-23 of thymosin beta-4 (LKKTETQ), not the 43-amino-acid protein — a distinction FDA preserves by listing the substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," while listing thymosin-alpha 1 as a separate entry entirely. A vial marked "TB-500" and a vial marked "thymosin beta-4" are not reliably the same molecule.

All four constituents appear on the same FDA page of bulk drug substances that may present significant safety risks in compounding: BPC-157, GHK-Cu for injectable routes, KPV, and the thymosin beta-4 fragment. For two of them — KPV and the TB-500 fragment — FDA states it has not identified any human exposure data for any route of administration.

Because there is no monograph, no approved combination product, and no published protocol, there is also no reference ratio. Two vials sold under the same blend name need not contain the same proportions, or the same peptides.

The research base for four-peptide combinations is sparse. Most studies, when they exist, focus on individual components or simpler pairings.

Until more robust data emerge, multi-peptide stacks are best viewed as speculative rather than evidence-based therapies.

For deeper dives on this peptide, see:

• BPC-157 + GHK-CU + TB-500 + KPV benefits and areas of interest
• BPC-157 + GHK-CU + TB-500 + KPV side effects and safety context
• BPC-157 + GHK-CU + TB-500 + KPV dosing concepts (educational)
• BPC-157 + GHK-CU + TB-500 + KPV research and evidence overview

Has this four-peptide combination ever been studied? No. No published study — human or animal — has administered BPC-157, GHK-Cu, TB-500, and KPV together, and no regulator has evaluated the combination. There is no trial, no case series, no pharmacokinetic work, and no standard ratio. That is the honest starting point for everything else on this page.

Does combining these peptides produce synergy? The one published experiment that tested a combination in this family found the opposite of the marketing claim. In 32 rats undergoing Achilles tendon transection and repair, TB-500 significantly increased maximum load to failure and significantly improved Bonar and Movin histology scores; BPC-157 was numerically better than control without reaching significance; and "combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone" (Biçer et al., Jt Dis Relat Surg 2026). The authors suggest the two may converge on shared downstream pathways. Adding two more peptides on top of that result is an assumption, not an extrapolation.

Can you verify what is actually in the vial? Not from the label. Independent testing of TB-500-labelled products by the UC Davis Maddy Laboratory for the Racing Medication and Testing Consortium found many contained no thymosin beta-4 or derived peptide, and most contained no protein, peptide, or amino acid at all; a single sample did contain N-acetylated LKKTETQ (RMTC bulletin). A four-component blend multiplies that uncertainty rather than averaging it out.

Is any human evidence coming? For one component, yes. A phase 1/2 randomised, placebo-controlled dose-escalation study of TB-500 in 80 adults with stable atherosclerotic cardiovascular disease began recruiting in February 2026, with estimated completion in 2028 (NCT07487363). Nothing comparable exists for BPC-157, GHK-Cu by injection, KPV, or any blend containing them.

How does this differ from the three-peptide version? Only by TB-500. The BPC-157 / GHK-Cu / KPV blend is the same product without it — and given that the head-to-head above found no additive benefit from pairing BPC-157 with TB-500, the fourth peptide adds a fourth set of unknowns, a fourth prohibited substance for tested athletes, and a fourth labelling claim, without a study showing it adds a fourth benefit.

Why do dosing discussions for this blend revolve around GHK-Cu? Because in a fixed combination the most limiting component sets the ceiling for all of them. GHK-Cu is the one associated with injection-site pain, and there are no published human trials of injectable GHK-Cu to establish a tolerable dose in the first place. So the amount of every other peptide delivered is governed by a constraint that itself has no evidence base — one more reason a fixed blend is harder to reason about than its parts.